Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies

Table 2

Descriptive statistics (all groups).

	CLL ()			CVID ()			Controls ()
	Median	Q1	Q3	Median	Q1	Q3	Median	Q1	Q3
IgG (g/L)	8.26	5.84	10.75	6.85	5.80	7.88	12.80	10.75	14.95
IgA (g/L)	0.82	0.48	1.69	0.07	0.07	0.14	2.58	1.96	3.12
IgM (g/L)	0.46	0.26	0.81	0.11	0.07	0.20	1.6	0.84	1.42
Anti-Gal IgG (U/mL)	45.88	13.69	80.21	31.60	27.50	39.50	64.01	30.80	144.90
Anti-Gal IgA (U/mL)	5.35	2.93	11.16	0.01	0.01	1.50	25.00	16.12	36.80
Anti-Gal IgM (U/mL)	5.70	1.97	11.31	1.60	0.50	6.68	27.80	14.90	48.68
Anti-PCP IgG (mg/L)	41.10	19.9	68.17	65.05	52.70	79.47	58.30	30.76	108.70
Anti-PCP IgG2 (mg/L)	13.73	7.5	24.49	—	—	—	15.24	7.26	33.10
Anti-PCP IgA (mg/L)	7.58	4.16	17.52	0.63	0.20	2.18	27.00	12.50	55.65

Because the data were not normally distributed, they are shown as the median, Q1 (first quartile), and Q3 (third quartile).